Current NANT Consortium Clinical Trials that are entering patients
Click to get more information about each trial:
- N99-02: Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) (NSC-326321) and Autologous Stem Cell Support For Recurrent High-Risk Neuroblastoma (NCI 68).
- N2001-02: A Phase II study of 131I-Metaiodobenzylguanidine (MIBG) with Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma.
- N2004-03: A Phase I study of intravenous fenretinide in pediatric neuroblastoma.
- N2004-04: A Phase I Study of Fenretinide Lym-X-SorbTM (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (IND # 68,254)
- N2004-06: Irinotecan and Vincristine with 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
- N2007-01: A Phase 2a Study of UltratraceTM Iobenguane I 131 in Patients with Relapsed/Refractory High-Risk Neuroblastoma
- N2007-02: A Phase I Study Of Bevacizumab With Bolus And Metronomic Cyclophosphamide And Zoledronic Acid In Children With Recurrent Or Refractory Neuroblastoma
- N2007-03: Vorinostat and MIBG in Recurrent or Resistant Neuroblastoma Patients
